Novartis won't take 'hint' as German HTA says Gilenya offers little additional benefit
This article was originally published in Scrip
Novartis's oral MS drug Gilenya (fingolimod) appears to have been 'damned with faint praise' as the German reimbursement process concluded that the drug only demonstrated "a hint of benefit", in comparison with interferon beta treatment and no benefit compared to Teva's Copaxone. Novartis put this down to "teething troubles" in the new German system and hopes that it will be remedied subsequently
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.